RedHill Biopharma announces positive new data with Opaganib for nuclear radiation injury
Positive in vivo results from a new study of opaganib in radiation-induced hematologic and renal toxicity reaffirms opaganib’s potential protective ...
Tag: opaganib
RedHill’s oral broad-acting antiviral, Opaganib, granted new COVID-19 treatment patent
TEL AVIV, Israel and RALEIGH, NC, October 19, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty ...
RedHill reports potent inhibition of Omicron with oral COVID-19 drug candidate opaganib in vitro
TEL AVIV, Israel and RALEIGH, NC, April 11, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty ...
RedHill Biopharma’s oral Opaganib reduces mortality by 70% given on top of Remdesivir and corticosteroids in severe COVID-19
TEL AVIV, Israel and RALEIGH, NC, February 7, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty ...
RedHill Biopharma reports that Opaganib mechanism not impacted by viral spike-protein mutations, including Omicron mutations
TEL AVIV, Israel and RALEIGH, NC, December 6, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty ...
RedHill Biopharma reports further analysis of phase 2/3 data including a 62% reduction in mortality with oral opaganib in moderately severe COVID-19 patients
62% statistically significant reduction in mortality shown for moderately severe COVID-19 patients group treated with opaganib vs. the placebo-controlled arm ...
-
Meteorites likely source of nitrogen for early Earth
-
New implants linked to less infection and better recovery from orthopedic surgery
-
‘Shocking’ discovery: Electricity from electric eels may transfer genetic material to nearby animals
-
New study identifies the greatest threat to wildlife across North America and Canada: people
-
Scientists build tiny biological robots from human cells
-
Why have so many new diseases developed in the bagged salads sector?